ETS1 regulates tissue-remodeling properties of specific fibroblast subtypes in the synovium, gut and cancer and thus emerges as a novel cross-tissue therapeutic target for modulation of pathogenic fibroblast activation.
This is a preview of subscription content, log in via an institution to check access.
References
Rivellese, F. et al. Nat. Med. 28, 1256–1268 (2022).
Yan, M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-022-01285-0 (2022).
Ryu, J. H. et al. PLoS Biol. 12, e1001881 (2014).
Okada, Y. et al. Nature 506, 376–381 (2014).
Ellinghaus, D. et al. Nat. Genet. 48, 510–518 (2016).
Ge, X. et al. Genome Biol. 22, 247 (2021).
Croft, A. P. et al. Nature 570, 246–251 (2019).
Wei, K. et al. Nature 582, 259–264 (2020).
Danks, L. et al. Ann. Rheum. Dis. 75, 1187–1195 (2016).
Takeuchi, T. et al. Ann. Rheum. Dis. 78, 899–907 (2019).
Korsunsky, I. et al. Med (NY) 3, 481–518 e414 (2022).
Wohlfahrt, T. et al. Nature 566, 344–349 (2019).
Liu, X. et al. Gastroenterology 158, 1728–1744 e1714 (2020).
Sun, M. et al. Ann. Rheum. Dis. 78, 1621–1631 (2019).
Friscic, J. et al. Immunity 54, 1002–1021 e1010 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Ospelt, C. A common activator of tissue-remodeling fibroblasts across tissues. Nat Immunol 23, 1295–1296 (2022). https://doi.org/10.1038/s41590-022-01294-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-022-01294-z
- Springer Nature America, Inc.
This article is cited by
-
Treatable Traits in Systemic Sclerosis
Clinical Reviews in Allergy & Immunology (2023)